同和药业 reported revenue of ¥0.38B for the period ended 2026-06-30, -10.4% year on year. Net income was ¥0.02B, a 6.4% net margin on a 28.1% gross margin. The largest revenue line is 医药原料药 at 91% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.38B | -10.4% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -58.0% |
| Gross margin | 28.1% | Net margin 6.4% |
| Revenue Q/Q | +7.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药原料药 | ¥0.35B | 91.1% |
| 医药中间体 | ¥0.03B | 8.8% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.28B | 71.9% |
| R&D | ¥0.04B | 9.4% |
| SG&A | ¥0.04B | 9.3% |
| Tax & other | ¥-0.00B | -1.2% |
| Item | Amount |
|---|---|
| Total assets | ¥3.18B |
| Total liabilities | ¥0.81B |
| Shareholders' equity | ¥2.37B |
| Equity / assets | 74.7% |
| Operating cash flow | ¥0.07B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | 371% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies